Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors

Journal of Thoracic Oncology

Volumn 12, Issue 11, 2017, Pages 1626-1635

  Feng, Sophie ^a   Coward, Jermaine ^a   McCaffrey, Elizabeth ^a   Coucher, John ^a   Kalokerinos, Paul ^b   O'Byrne, Ken ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b Neo Cancer Care   (Australia)

Author keywords

Encephalopathy; Immune related adverse event; Immunotherapy; Non small cell lung cancer; Pembrolizumab

Indexed keywords

CARBOPLATIN; CHECKPOINT KINASE INHIBITOR; CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; METHYLPREDNISOLONE; PEMBROLIZUMAB; PEMETREXED; PREDNISOLONE; MONOCLONAL ANTIBODY;

AGED; ATAXIA; BRAIN DISEASE; BRAIN METASTASIS; CASE REPORT; CLINICAL ARTICLE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPHASIA; ELECTROENCEPHALOGRAPHY; FRONTAL LOBE; HUMAN; HUMAN TISSUE; INCIDENCE; LUNG LOBECTOMY; MALE; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RIGHT HEMISPHERE; RISK FACTOR; SENSORY NEUROPATHY; SOLID MALIGNANT NEOPLASM; SOMNOLENCE; WHOLE BRAIN RADIOTHERAPY; CHEMICALLY INDUCED; IMMUNOTHERAPY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN DISEASES; HUMANS; IMMUNOTHERAPY; MALE;

EID: 85032433088     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.08.007     Document Type: Review

References (45)

1. Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
2. Motzer, R., Escudier, B., McDermott, D., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
3. Bellmunt, J., de Wit, R., Vaughn, D., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376 (2017), 1015–1026.
4. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
5. Decatris, M.P., O'Byrne, K.J., Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small cell lung cancer. Future Oncol 12 (2016), 1805–1822.
6. Kyi, C., Postow, M.A., Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588 (2014), 368–376.
7. O'Byrne, K., Stimulating immune responses to fight cancer: basic biology and mechanisms. Asia Pac J Clin Oncol 11:suppl 1 (2015), 9–15.
8. Michot, J., Bigenwald, C., Champiat, S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54 (2016), 139–148.
9. Salam, S., Lavin, T., Turan, A., Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep, 23, 2016, 2016.
10. Khoja, L., Maurice, C., Chappell, M., et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 4 (2016), 175–178.
11. Mandel, J., Olar, A., Aldape, K., Tremont-Lukats, I.W., Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 344 (2014), 229–231.
12. Maleissye, M., Nicolas, G., Saiag, P., Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375 (2016), 296–297.
13. Maurice, C., Schneider, R., Kiehl, T., et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res 3 (2015), 1299–1302.
14. Bompaire, F., Mateus, C., Taillia, H., et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Invest New Drugs 30 (2012), 2407–2410.
15. Abdallah, A.O., Herlopian, A., Ravilla, R., et al. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature. J Oncol Pharm Pract 22 (2016), 537–542.
16. Carl, D., Grullich, C., Hering, S., Schabet, M., Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC Res Notes, 8, 2015, 316.
17. Voskens, C.J., Goldinger, S.M., Loquai, C., et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One, 8, 2013, e53745.
18. Maur, M., Tomasello, C., Frassoldati, A., Dieci, M.V., Barbieri, E., Conte, P., Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 30 (2012), e76–e78.
19. Bot, I., Blank, C.U., Boogerd, W., Brandsma, D., Neurological immune-related adverse events of ipilimumab. Pract Neurol 13 (2013), 278–280.
20. Williams, T.J., Benavides, D.R., Patrice, K.A., et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol, 73, 2016, 928e33.
21. Liao, B., Shroff, S., Kamiya-Matsuoka, C., Tummala, S., Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16 (2014), 589–593.
22. Boyd, K., Kalladka, D., Overell, J., Waterston, A., Ipilimumab induced encephalitis: a case report. Immunome Research 11 (2015), 1–3.
23. Stein, M.K., Summers, B.B., Wong, C.A., Box, H.L., Cleveland, K.O., Meningoencephalitis following ipilimumab administration in metastatic melanoma. Am J Med Sci 350 (2015), 512–513.
24. Wilgenhof, S., Neyns, B., Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 22 (2011), 991–993.
25. Bhatia, S., Huber, B., Upton, M., Thompson, J.A., Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 32 (2009), 203–205.
26. Loochtan, A., Nickolich, M., Hobson-Webb, L., Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52 (2015), 307–308.
27. Quirk, S., Shure, A., Agrawal, D., Immune-mediated adverse effects of anti-CTLA-4 antibody therapy in metastatic melanoma. Transl Res 166 (2015), 412–424.
28. Kawamoto, S., Tran, T., Maruya, M., et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science 336 (2012), 485–489.
29. Berman, D., Parker, S., Siegel, J., Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 10 (2010), 1–10.
30. Gonzalez, N., Puwanant, A., Lu, A., Marks, S.M., Živković S.A., Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromusc Disord 27 (2017), 266–268.
31. Arriola, E., Wheater, M., Galea, I., Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J Thorac Oncol 11 (2016), 1511–1521.
32. Manousakis, G., Koch, J., Sommerville, B., et al. Multifocal polyradiculopathy during ipilimumab treatment of melanoma. Muscle Nerve 48 (2013), 440–444.
33. Blackmon, J., Viator, T., Conry, R., Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromed 1 (2016), 39–45.
34. Bjoern, J., Nitchske, N., Iversen, T., Schmidt, H., Fode, K., Svane, I.M., Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with ipilimumab. Oncoimmunology, 5, 2016, e1100788.
35. Petkovic, F., Castellano, B., The role of interleukin-6 in central nervous system demyelination. Neur Reg Res 11 (2016), 1922–1923.
36. Cuzzubbo, S., Javeri, F., Tissier, M., Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73 (2017), 1–8.
37. Spain, L., Walls, G., Julve, M., et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28 (2016), 377–385.
38. Zimmer, L., Goldinger, S.M., Hofmann, L., et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 210–225.
39. Eggermont, A.M.M., Chiarion-Sileni, V., Grob, J.-J., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16 (2015), 522–530.
40. Johnson, D.B., Sullivan, R.J., Ott, P.A., et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2 (2016), 234–240.
41. Gutzmer, R., Koop, A., Meier, F., et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Can 75 (2017), 24–32.
42. Salama, A., Postow, M., Salama, J., Irradiation and immunotherapy: from concept to the clinic. Cancer 122 (2016), 1659–1671.
43. Du Four, S., Hong, A., Chan, M., et al. Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients [serial online]. Case Rep Oncol Med, 2014, 2014, 417913.
44. Illadolid, J., Amin, A., Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4 (2015), 560–575.
45. Smith, J., Menzies, A., Cohen, J., et al. Neurotoxicity associated with anti-PD1 therapy: a multi-center case series. [abstract] J Clin Oncol, 35(suppl), 2017, e21641.